Showing posts with label SkyCell. Show all posts
Showing posts with label SkyCell. Show all posts

Thursday, 13 May 2021

LOT Polish Airlines and SkyCell, sign an agreement that extending LOT Cargo’s capabilities in the transport of medicines and pharmaceutical products (PIL).

 
LOT Polish Airlines and SkyCell, a Swiss provider of hybrid containers, signed an agreement that extends LOT Cargo’s capabilities in the transport of medicines and pharmaceutical products (PIL). 


Thanks to advanced technology, SkyCell’s hybrid containers guarantee to maintain a constant transport temperature necessary for transporting demanding shipments even to  distant regions of the world.


The transport of pharmaceutical products requires the airlines to apply specialist solutions and meet demanding standards guaranteeing safety and the highest quality of provided services. Pharma and Life-Science is a critical sector of global cargo transport for LOT; therefore, the company is constantly increasing its competencies and improving its offer addressed to companies operating in this industry. 



In July 2020, LOT Cargo obtained the IATA CEIV Pharma certificate, which gave the Polish carrier a place in the prestigious group of 25 airlines with a documented and approved PIL QMS Quality Management System for pharmaceutical shipment management.

Thursday, 6 May 2021

SkyCell and DB Schenker sign new partnership deal



DB Schenker increases response to the pandemic by signing a Master Lease Agreement (MLA) with SkyCell. The partnership enables DB Schenker to enhance its vaccine logistics service solutions with additional flexibility through the new healthcare product DB SCHENKERlife+. Based in Switzerland, SkyCell manufactures innovative temperature-controlled air freight containers for pharmaceutical supply chains that can maintain internal temperatures as low as -80°C to -15°C for a minimum of five days, and temperatures of +2°C to +8°C and +15°C to +25°C for more than eight days. As part of the new partnership with SkyCell, DB Schenker’s service portfolio is extended by an additional reliable packaging solution to transport lifesaving pharmaceutical products, such as vaccines against Covid-19, globally. 

Milestone agreement for the lease of SkyCell’s hybrid pharma containers • Containers maintain constant temperatures for more than a week • Suitable for all Covid-19 vaccines on the market 



Thorsten Meincke, Global Board Member for Air & Ocean Freight at DB Schenker: “Logistics matters extensively in trying to overcome the pandemic and DB Schenker is already transporting Covid-19 vaccines worldwide. With this agreement, we upgrade our existing broad portfolio of healthcare-related logistics services with even more capability for our customers for the widespread roll-out of global vaccinations. With SkyCell, we have found an excellent partner in this endeavor to provide high quality on a global level.” 

Wednesday, 5 May 2021

DB Schenker signs partnership with SkyCell: Temperature-controlled containers for lifesaving medicine and Covid-19 vaccines

DB Schenker increases response to the pandemic by signing a Master Lease Agreement (MLA) with SkyCell. The partnership enables DB Schenker to enhance its vaccine logistics service solutions with additional flexibility through the new healthcare product DB SCHENKERlife+. Based in Switzerland, SkyCell manufactures innovative temperature-controlled air freight containers for pharmaceutical supply chains that can maintain internal temperatures as low as -80°C to -15°C for a minimum of five days, and temperatures of +2°C to +8°C and +15°C to +25°C for more than eight days. As part of the new partnership with SkyCell, DB Schenker’s service portfolio is extended by an additional reliable packaging solution to transport lifesaving pharmaceutical products, such as vaccines against Covid-19, globally. 

Milestone agreement for the lease of SkyCell’s hybrid pharma containers • Containers maintain constant temperatures for more than a week • Suitable for all Covid-19 vaccines on the market 



Thorsten Meincke, Global Board Member for Air & Ocean Freight at DB Schenker: “Logistics matters extensively in trying to overcome the pandemic and DB Schenker is already transporting Covid-19 vaccines worldwide. With this agreement, we upgrade our existing broad portfolio of healthcare-related logistics services with even more capability for our customers for the widespread roll-out of global vaccinations. With SkyCell, we have found an excellent partner in this endeavor to provide high quality on a global level.” 

Wednesday, 14 April 2021

Virgin Atlantic to ship vaccines through partnership with SkyCell

Virgin Atlantic’s Pharma service will use SkyCell’s temperature-controlled containers to ship valuable, life-saving pharmaceuticals


                                       SkyCell, one of the leading manufacturers of innovative pharma containers, has partnered with Virgin Atlantic to contribute to its safe, secure, and sustainable shipment of valuable vaccines and pharma products. Virgin Atlantic will use SkyCell containers covering the full range of biologics transit temperature requirements: -80°C, -25°C to -15°C, +2°C to +8°C, and up to +15°C to + 25°C.

The partnership will give customers confidence that their pharmaceutical shipments will arrive at destination safely, as the innovative hybrid containers - which have an average runtime of 202 hours - have a failure rate of less than 0.1%. This is compared to an industry standard failure rate of up to 12%, which cost the pharma industry $34.1 billion in 2019 alone.